Recently, the inhibitor entered clinical trials for the treatment of patients with advanced solid tumors including glioma, chondrosarcoma, and cholangiocarcinoma with a mutated IDH2 (Table 1). The gene discussed is IDH2; the disease is central nervous system cancer.